Nivolumab is an immune checkpoint inhibitor approved for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma. This immunotherapeutic agent is associated with immune-related adverse events that require prompt identification for successful management and resolution.
The use of monoclonal antibodies in the treatment of cancer is rapidly evolving. These immunomodulating agents are associated with an increased incidence of hypersensitivity reaction. Prompt identification and effective management is essential for optimal patient care.
Results 11 - 20 of 412